Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119262 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT00119262: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00119262 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 226 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00119262, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with more than one chemotherapy drug (combination chemotherapy), may be a better way to block tumor growth.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL bevacizumab
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119262
The ClinicalTrials.gov registry entry for NCT00119262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00119262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119262 about?
NCT00119262 is a clinical study titled "Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer". This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some bl...
What is the current status of trial NCT00119262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2005-10. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00119262?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), bevacizumab (BIOLOGICAL), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00119262?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.